Gamma camera probe developer Neoprobe reported second-quarter sales of $1.7 million, up 26% compared with the $1.3 million posted in the second quarter of 2004. For the period (end-June 30), the Dublin, OH-based firm had a net loss of $1.3 million, compared with a net loss of $430,000 last year.
The 2005 second-quarter net loss included $322,000 in noncash charges, compared with noncash charges of $243,000 in the second quarter of 2004. Neoprobe CFO Brent Larson said that the second quarter featured strong gamma device prices and unit volumes, as well as increased sales of extended service contracts sold through the vendor's primary gamma device marketing partner.
The increase in operating expenses was primarily due to nonclinical testing, as well as drug manufacturing validation and production activities associated with the company's Lymphoseek radiopharmaceutical, Neoprobe said.
By AuntMinnie.com staff writers
August 2, 2005
Related Reading
Neoprobe inks new Lymphoseek deal, April 21, 2005
Neoprobe gets new Quantix/OR clearance, February 15, 2005
Neoprobe extends Japanese distribution deal, August 25, 2004
Neoprobe reports Q1 results, May 13, 2004
Neoprobe trims losses in 2003, March 9, 2004
Copyright © 2005 AuntMinnie.com
